The risk of hepatitis B virus reactivation is considerably high during sorafenib therapy in patients with advanced hepatocellular carcinoma

2017 ◽  
Vol 66 (1) ◽  
pp. S449-S450 ◽  
Author(s):  
S.J. Suh ◽  
H.J. Yim ◽  
J.H. Seo ◽  
Y.S. Lee ◽  
J.J. Hyun ◽  
...  
Sign in / Sign up

Export Citation Format

Share Document